

# Contents

Foreword VII  
Preface XXI  
About the Editor XXV  
List of Contributors XXVII

1 **An Overview** 1  
*Goutam Brahmachari*

2 **Use of Chemical Genomics to Investigate the Mechanism of Action for Inhibitory Bioactive Natural Compounds** 9  
*Daniel Burnside, Houman Moteshareie, Imelda G. Marquez, Mohsen Hooshyar, Bahram Samanfar, Kristina Shostak, Katayoun Omid, Harry E. Peery, Myron L. Smith, and Ashkan Golshani*

2.1 Introduction: Antibiotic Resistance and the Use of Natural Products as a Source for Novel Antimicrobials 9

2.2 Chemical Genetics and Genomics 10

2.3 Development of GDA Technology 11

2.3.1 The Use of Gene Deletion Arrays (GDAs) to Investigate MOA 12

2.3.2 Chemical Genetic Interactions 12

2.3.3 Quantifying Genetic and Chemical Genetic Interactions 14

2.3.4 Data Analysis 15

2.3.5 Platforms for Chemical Genomic GDA Studies 17

2.3.6 Why Screen Natural Products in GDAs? 19

2.3.7 Successful Applications of GDA Technology 21

2.4 Concluding Remarks 22

Abbreviations 24

References 24

|          |  |           |
|----------|--|-----------|
| <b>3</b> | <b>High-Throughput Drug Screening Based on Cancer Signaling in Natural Product Screening</b>                                       | <b>33</b> |
|          | <i>Xinxin Zhang, Yuping Du, and Jinbo Yang</i>   |           |
| 3.1      | Introduction   | 33        |
| 3.2      | Cancer Signaling Pathways with Their Own Drug Screening Assays in HTS  | 35        |
| 3.2.1    | $\beta$ -Galactosidase Enzyme Complementation Assays for EGFR Signaling Drug Screening   | 35        |
| 3.2.2    | Fluorescence Superquenching Assays for PI3Ks Signaling Drug Screening  | 35        |
| 3.2.3    | TOP Flash Reporter Gene Assays for Wnt Signaling Drug Screening  | 36        |
| 3.2.4    | Luciferase Reporter Gene Assays for STATs Signaling Drug Screening   | 37        |
| 3.3      | Concluding Remarks   | 37        |
|          | Abbreviations  | 38        |
|          | References   | 38        |
| <br>     |  |           |
| <b>4</b> | <b>Immunosuppressants: Remarkable Microbial Products</b>   | <b>43</b> |
|          | <i>Preeti Vaishnav, Young J. Yoo, Yeo J. Yoon, and Arnold L. Demain</i>  |           |
| 4.1      | Introduction   | 43        |
| 4.2      | Discovery  | 44        |
| 4.3      | Mode of Action   | 47        |
| 4.4      | Biosynthesis   | 49        |
| 4.4.1    | Acetate, Propionate, Butyrate, Methionine, and Valine as Precursors of the Macrolide Rings of Sirolimus, Ascomycin, and Tacrolimus | 49        |
| 4.4.2    | Pipicolate Moiety of the Macrolide Ring of Sirolimus, Ascomycin, and Tacrolimus  | 52        |
| 4.4.3    | The Final Step in Biosynthesis of Ascomycins and Tacrolimus  | 55        |
| 4.4.4    | Formation of the Substituted Cyclohexyl Moiety of Sirolimus, Tacrolimus, and Ascomycins  | 58        |
| 4.4.5    | Biosynthesis of Cyclosporin  | 61        |
| 4.5      | Genetics and Strain Improvement  | 63        |
| 4.6      | Fermentation and Nutritional Studies   | 65        |
| 4.7      | Other Activities of Immunosuppressants   | 69        |
| 4.8      | Concluding Remarks   | 71        |
|          | Acknowledgments  | 72        |
|          | References   | 72        |

|          |  |
|----------|--|
| <b>5</b> | <b>Activators and Inhibitors of ADAM-10 for Management of Cancer and Alzheimer's Disease</b> 83          |
|          | <i>Prajakta Kulkarni, Manas K. Haldar, and Sanku Mallik</i>  |
| 5.1      | Introduction to ADAM Family of Enzymes 83  |
| 5.2      | ADAM-10 Structure and Physiological Roles 85   |
| 5.3      | Pathological Significance 85   |
| 5.3.1    | Modulating ADAM Activity in Neurodegeneration 85   |
| 5.3.2    | ADAM-10 in Cancer Pathology 86   |
| 5.4      | ADAM-10 as Potential Drug Target 87  |
| 5.5      | Synthetic Inhibitors of ADAM-10 88   |
| 5.6      | Natural Products as Activators and Inhibitors for ADAM-10 92   |
| 5.7      | Natural Products as ADAM-10 Activators 93  |
| 5.7.1    | Ginsenoside R 94   |
| 5.7.2    | <i>Curcuma longa</i> 94  |
| 5.7.3    | <i>Ginkgo biloba</i> 95  |
| 5.7.4    | Green Tea 95   |
| 5.8      | Natural Products as ADAM-10 Inhibitors 96  |
| 5.8.1    | Triptolide 96  |
| 5.8.1.1  | Novel Derivatives and Carriers of Triptolide 98  |
| 5.9      | Concluding Remarks 99  |
|          | Abbreviations 99   |
|          | References 99  |
| <br>     |  |
| <b>6</b> | <b>Structure and Biological Activity of Polyether Ionophores and Their Semisynthetic Derivatives</b> 107 |
|          | <i>Michał Antoszczak, Jacek Rutkowski, and Adam Huczyński</i>  |
| 6.1      | Introduction 107   |
| 6.2      | Structures of Polyether Ionophores and Their Derivatives 108   |
| 6.2.1    | Monensin and Its Derivatives 112   |
| 6.2.2    | Salinomycin and Its Derivatives 117  |
| 6.2.3    | Lasalocid Acid A and Its Derivatives 118   |
| 6.2.4    | Other Polyether Ionophores 125   |
| 6.2.4.1  | Ionophores with Monensin Skeleton 125  |
| 6.2.4.2  | Polyether Ionophores with Dianemycin Skeleton 126  |
| 6.3      | Chemical Properties of Polyether Ionophores and Their Derivatives 130                                    |
| 6.3.1    | Complexes of Ionophores with Metal Cations 130   |
| 6.3.2    | Mechanism of Cation Transport 132  |
| 6.4      | Biological Activity 133  |

|          |   |            |
|----------|---|------------|
| 6.4.1    | Antibacterial Activity of Polyether Antibiotics and Their Derivatives   | 135        |
| 6.4.2    | Antifungal Activity of Polyether Antibiotics and Their Derivatives  | 140        |
| 6.4.3    | Antiparasitic Activity of Polyether Antibiotics and Their Derivatives   | 141        |
| 6.4.4    | Antiviral Activity of Polyether Antibiotics   | 144        |
| 6.4.5    | Anticancer Activity of Polyether Antibiotics and Their Derivatives  | 145        |
| 6.5      | Concluding Remarks  | 153        |
|          | Abbreviations   | 154        |
|          | References  | 155        |
| <b>7</b> | <b>Bioactive Flavaglines: Synthesis and Pharmacology</b>  | <b>171</b> |
|          | <i>Christine Basmadjian, Qian Zhao, Armand de Gramont, Maria Serova, Sandrine Faivre, Eric Raymond, Stephan Vagner, Caroline Robert, Canan G. Nebigil, and Laurent Désaubry</i> |            |
| 7.1      | Introduction  | 171        |
| 7.2      | Biosynthetic Aspects  | 172        |
| 7.3      | Synthesis of Flavaglines  | 174        |
| 7.3.1    | Chemical Syntheses  | 174        |
| 7.3.2    | Biomimetic Synthesis of Flavaglines   | 179        |
| 7.3.3    | Synthesis of Silvestrol (6)   | 182        |
| 7.4      | Pharmacological Properties of Flavaglines   | 184        |
| 7.4.1    | Anticancer Activity   | 184        |
| 7.4.2    | Anti-inflammatory and Immunosuppressant Activities  | 190        |
| 7.4.3    | Cytoprotective Activity   | 190        |
| 7.4.4    | Antimalarial Activities   | 191        |
| 7.5      | Structure – Activity Relationships (SARs)   | 192        |
| 7.6      | Concluding Remarks  | 192        |
|          | Abbreviations   | 193        |
|          | References  | 194        |
| <b>8</b> | <b>Beneficial Effect of Naturally Occurring Antioxidants against Oxidative Stress – Mediated Organ Dysfunctions</b>   | <b>199</b> |
|          | <i>Pabitra B. Pal, Shatadal Ghosh, and Parames C. Sil</i>   |            |
| 8.1      | Introduction  | 199        |
| 8.2      | Oxidative Stress and Antioxidants   | 200        |
| 8.2.1    | Mangiferin and Its Beneficial Properties  | 200        |
| 8.2.1.1  | Antioxidant Activity of Mangiferin  | 200        |
| 8.2.1.2  | Anti-inflammatory Activity of Mangiferin  | 201        |
| 8.2.1.3  | Immunomodulatory Effect   | 202        |
| 8.2.1.4  | Antidiabetic Activity   | 203        |

|         |   |     |
|---------|---|-----|
| 8.2.1.5 | Iron Complexing Activity of Mangiferin  | 205 |
| 8.2.1.6 | Mangiferin Protects against Mercury-Induced Toxicity  | 205 |
| 8.2.1.7 | Mangiferin Protects Murine Liver against Pb(II)-Induced Hepatic Damage                      | 206 |
| 8.2.2   | Arjunolic Acid  | 207 |
| 8.2.2.1 | Cardioprotective Effects of Arjunolic Acid  | 208 |
| 8.2.2.2 | Antidiabetic Activity   | 211 |
| 8.2.2.3 | Arjunolic Acid Protects Organs from Acetaminophen (APAP)-Induced Toxicity                   | 211 |
| 8.2.2.4 | Arjunolic Acid Protects Liver from Sodium Fluoride-Induced Toxicity                         | 212 |
| 8.2.2.5 | Protection against Arsenic-Induced Toxicity   | 212 |
| 8.2.2.6 | Mechanism of Action of Arjunolic Acid   | 214 |
| 8.2.3   | Baicalein   | 214 |
| 8.2.3.1 | Baicalein Protects Human Melanocytes from H <sub>2</sub> O <sub>2</sub> -Induced Apoptosis  | 215 |
| 8.2.3.2 | Protection against Doxorubicin-Induced Cardiotoxicity                                       | 215 |
| 8.2.4   | Silymarin   | 216 |
| 8.2.4.1 | Physicochemical and Pharmacokinetic Properties of Silymarin                                 | 216 |
| 8.2.4.2 | Metabolism of Silymarin   | 217 |
| 8.2.4.3 | Antioxidant Activity of Silymarin   | 217 |
| 8.2.4.4 | Protective Effect of Silydianin against Reactive Oxygen Species                             | 219 |
| 8.2.4.5 | Diabetes and Silymarin  | 219 |
| 8.2.4.6 | Silibinin Protects H9c2 Cardiac Cells from Oxidative Stress                                 | 219 |
| 8.2.4.7 | Silymarin Protects Liver from Doxorubicin-Induced Oxidative Damage                          | 220 |
| 8.2.4.8 | Silymarin and Hepatoprotection  | 220 |
| 8.2.4.9 | Stimulation of Liver Regeneration   | 221 |
| 8.2.5   | Curcumin  | 221 |
| 8.2.5.1 | Chemical Composition of Turmeric  | 222 |
| 8.2.5.2 | Metabolism of Curcumin  | 222 |
| 8.2.5.3 | Antioxidant Activity of Curcumin  | 222 |
| 8.2.5.4 | Diabetes and Curcumin   | 225 |
| 8.2.5.5 | Efficacy of Biodegradable Curcumin Nanoparticles in Delaying Cataract in Diabetic Rat Model | 226 |
| 8.3     | Concluding Remarks  | 227 |
|         | Abbreviations   | 227 |
|         | References  | 228 |

## **9 Isoquinoline Alkaloids and Their Analogs: Nucleic Acid and Protein Binding Aspects, and Therapeutic Potential for Drug Design 241**

*Gopinatha S. Kumar*

### **9.1 Introduction 241**

|         |  |     |
|---------|--|-----|
| 9.2     | Isoquinoline Alkaloids and Their Analogs   | 243 |
| 9.2.1   | Berberine  | 243 |
| 9.2.1.1 | Interaction of Berberine with Deoxyribonucleic Acids   | 244 |
| 9.2.1.2 | DNA Binding of Berberine Analogs   | 245 |
| 9.2.1.3 | Binding of Berberine and Analogs to Polymorphic DNA Conformations                                      | 248 |
| 9.2.1.4 | Interaction of Berberine and Analogs with Ribonucleic Acids  | 253 |
| 9.2.1.5 | Interaction of Berberine and Analogs with Proteins   | 258 |
| 9.2.2   | Palmatine  | 260 |
| 9.2.2.1 | Interaction of Palmatine and Analogs to Deoxyribonucleic Acids   | 261 |
| 9.2.2.2 | Interaction of Palmatine with RNA  | 262 |
| 9.2.2.3 | Interactions of Palmatine with Proteins  | 264 |
| 9.2.3   | Other Isoquinoline Alkaloids: Jatrorrhizine, Copticine, and Analogs – DNA/RNA and Protein Interactions | 266 |
| 9.3     | Concluding Remarks   | 267 |
|         | Acknowledgments  | 268 |
|         | Abbreviations  | 268 |
|         | References   | 269 |

**10 The Potential of Peptides and Depsipeptides from Terrestrial and Marine Organisms in the Fight against Human Protozoan Diseases** 279

*Jean Fotie*

|         |  |     |
|---------|--|-----|
| 10.1    | Introduction   | 279 |
| 10.2    | Antiprotozoan Peptides and Depsipeptides of Natural Origin and Their Synthetic Analogs | 281 |
| 10.2.1  | Apicidins  | 281 |
| 10.2.2  | Almiramides and Dragonamides   | 282 |
| 10.2.3  | Balgacyclamides  | 285 |
| 10.2.4  | Beauvericins and Allobauvericin  | 286 |
| 10.2.5  | Aerucyclamides   | 286 |
| 10.2.6  | Chondramides and Jaspamides  | 288 |
| 10.2.7  | Enniatins and Beauvenniatis  | 289 |
| 10.2.8  | Gallinamide A, Dolastatin 10 and 15, and Symplostatin 4                                | 290 |
| 10.2.9  | Hirsutatins and Hirsutellides  | 291 |
| 10.2.10 | Alamethicin  | 292 |
| 10.2.11 | Gramicidins  | 293 |
| 10.2.12 | Kahalalides  | 294 |
| 10.2.13 | Lagunamides  | 295 |
| 10.2.14 | Paecilodepsipeptides   | 295 |
| 10.2.15 | Pullularins  | 296 |
| 10.2.16 | Szentiamide  | 297 |

|         |                    |     |
|---------|--------------------|-----|
| 10.2.17 | Venturamides       | 297 |
| 10.2.18 | Viridamides        | 298 |
| 10.2.19 | Antiamoebin I      | 299 |
| 10.2.20 | Efraeptins         | 299 |
| 10.2.21 | Valinomycin        | 300 |
| 10.2.22 | Cyclosporins       | 300 |
| 10.2.23 | Cyclinopeptides    | 301 |
| 10.2.24 | Cycloaspeptides    | 302 |
| 10.2.25 | Mollamides         | 302 |
| 10.2.26 | Tsushimycin        | 303 |
| 10.2.27 | Leucinostatins     | 304 |
| 10.2.28 | Cardinalisamides   | 304 |
| 10.2.29 | Symplocamide A     | 305 |
| 10.2.30 | Xenobactin         | 305 |
| 10.3    | Concluding Remarks | 306 |
|         | Abbreviations      | 307 |
|         | References         | 307 |

## **11 Sesquiterpene Lactones: A Versatile Class of Structurally Diverse Natural Products and Their Semisynthetic Analogs as Potential Anticancer Agents** 321

*Devdutt Chaturvedi, Parmesh Kumar Dwivedi, and Mamta Mishra*

|           |  |     |
|-----------|--|-----|
| 11.1      | Introduction: Structural Features and Natural Distribution         | 321 |
| 11.2      | Anticancer Activity of Sesquiterpenes Lactones                     | 323 |
| 11.2.1    | Costunolide and Analogs  | 324 |
| 11.2.2    | Parthenolide and Analogs   | 328 |
| 11.2.3    | Helenalin and Analogs  | 331 |
| 11.2.4    | Artemisinin and Its Derivatives                                    | 332 |
| 11.2.5    | Tournefortin and Its Derivatives                                   | 333 |
| 11.2.6    | Eupalinin  | 333 |
| 11.2.7    | Inuviscolide and Related Compounds                                 | 334 |
| 11.2.8    | Japonicones  | 335 |
| 11.2.9    | Isoalantolactone and Related Compounds                             | 335 |
| 11.2.10   | 6-O-Angeloylenolin   | 336 |
| 11.2.11   | Miscellaneous STLs Under Different Classes                         | 336 |
| 11.2.11.1 | Guaianolides   | 336 |
| 11.2.11.2 | Pseudoguaianolides   | 339 |
| 11.2.11.3 | Eudesmanolides   | 339 |
| 11.2.11.4 | Germacranolide   | 340 |
| 11.2.11.5 | Other Anticancer Sesquiterpene Lactones                            | 340 |
| 11.3      | Structure–Activity Relationships (SARs) of Sesquiterpenes Lactones | 340 |

|           |   |            |
|-----------|---|------------|
| 11.4      | Concluding Remarks  | 341        |
|           | Acknowledgments   | 342        |
|           | Abbreviations   | 342        |
|           | References  | 342        |
| <b>12</b> | <b>Naturally Occurring Calanolides: Chemistry and Biology</b>   | <b>349</b> |
|           | <i>Goutam Brahmachari</i>   |            |
| 12.1      | Introduction  | 349        |
| 12.2      | Naturally Occurring Calanolides: Structures and Physical Properties   | 350        |
| 12.3      | Anti-HIV and Antituberculosis Potential of Calanolides  | 350        |
| 12.3.1    | Anti-HIV Potential of Calanolides   | 350        |
| 12.3.2    | Studies on Structure–Activity Relationships (SARs) of Calanolides   | 355        |
| 12.3.3    | Antituberculosis Potential of Calanolides and Related Derivatives   | 357        |
| 12.4      | Total Syntheses of Calanolides  | 360        |
| 12.5      | Concluding Remarks  | 369        |
|           | Acknowledgment and Disclosure   | 370        |
|           | Abbreviations   | 370        |
|           | References  | 371        |
| <b>13</b> | <b>Selective Estrogen Receptor Modulators (SERMs) from Plants</b>   | <b>375</b> |
|           | <i>Divya Lakshmanan Mangalath and Chittalakkottu Sadasivan</i>  |            |
| 13.1      | Introduction  | 375        |
| 13.2      | Structure of Estrogen Receptor  | 376        |
| 13.3      | Estrogen Receptor Signaling   | 377        |
| 13.4      | Selective Estrogen Receptor Modulators from Plants  | 379        |
| 13.5      | Molecular Basis of the Distinct SERM Action   | 381        |
| 13.6      | SERMs in the Treatment of Estrogen-Mediated Cancers   | 383        |
| 13.7      | Concluding Remarks  | 383        |
|           | Abbreviations   | 384        |
|           | References  | 384        |
| <b>14</b> | <b>Introduction to the Biosynthesis and Biological Activities of Phenylpropanoids</b>                             | <b>387</b> |
|           | <i>Luzia V. Modolo, Cristiane J. da Silva, Fernanda G. da Silva, Leonardo da Silva Neto, and Ângelo de Fátima</i> |            |
| 14.1      | Introduction  | 387        |
| 14.2      | Biosynthesis of Phenylpropanoids  | 387        |



|          |   |     |
|----------|---|-----|
| 14.3     | Some Phenylpropanoid Subclasses   | 392 |
| 14.3.1   | Flavonoids  | 392 |
| 14.3.1.1 | Function in Plants  | 392 |
| 14.3.1.2 | Pharmacological Properties  | 393 |
| 14.3.2   | Coumarins   | 395 |
| 14.3.2.1 | Function in Plants  | 395 |
| 14.3.2.2 | Pharmacological Properties  | 396 |
| 14.3.3   | Stilbenes   | 398 |
| 14.3.3.1 | Function in Plants  | 398 |
| 14.3.3.2 | Pharmacological Properties  | 399 |
| 14.4     | Concluding Remarks  | 400 |
|          | Acknowledgments   | 400 |
|          | Abbreviations   | 400 |
|          | References  | 401 |
| <br>     |   |     |
| 15       | <b>Neuropeptides: Active Neuromodulators Involved in the Pathophysiology of Suicidal Behavior and Major Affective Disorders</b> | 409 |
|          | <i>Gianluca Serafini, Daniel Lindqvist, Lena Brundin, Yogesh Dwivedi, Paolo Girardi, and Mario Amore</i>                        |     |
| 15.1     | Introduction  | 409 |
| 15.2     | Methods   | 410 |
| 15.3     | Involvement of Neuropeptides in the Pathophysiology of Suicidal Behavior and Major Affective Disorders                          | 411 |
| 15.3.1   | Corticotropin-Releasing Factor  | 411 |
| 15.3.2   | Arginine Vasopressin  | 412 |
| 15.3.3   | Oxytocin  | 413 |
| 15.3.4   | Galanin   | 415 |
| 15.3.5   | Tachykinins   | 415 |
| 15.3.6   | Neuropeptide Y  | 418 |
| 15.3.7   | Cholecystokinin   | 418 |
| 15.3.8   | Dynorphins  | 420 |
| 15.3.9   | Orexin  | 420 |
| 15.3.10  | Neurotensin   | 423 |
| 15.3.11  | Nociceptin  | 424 |
| 15.3.12  | Melanin-Concentrating Hormone   | 424 |
| 15.3.13  | Neuropeptide S  | 425 |
| 15.4     | The Association between Neuropeptides, Suicidality, and Major Affective Disorders   | 426 |
| 15.5     | Discussion of the Main Findings   | 429 |
| 15.6     | Concluding Remarks  | 431 |
|          | Abbreviations   | 432 |
|          | References  | 433 |

|           |  |            |
|-----------|--|------------|
| <b>16</b> | <b>From Marine Organism to Potential Drug: Using Innovative Techniques to Identify and Characterize Novel Compounds – a Bottom-Up Approach</b> | <b>443</b> |
|           | <i>A. Jonathan Singh, Jessica J. Field, Paul H. Atkinson, Peter T. Northcote, and John H. Miller</i>   |            |
| 16.1      | Introduction   | 443        |
| 16.2      | Structural Screening Approach  | 445        |
| 16.2.1    | Case Study 1: Colensolide from <i>Osmundaria colensoi</i>  | 448        |
| 16.2.2    | Case Study 2: Zampanolide from <i>Cacospongia mycofijiensis</i>  | 449        |
| 16.3      | Testing for Bioactivity by Screening in Mammalian Cells  | 452        |
| 16.4      | Chemical Genetics and Network Pharmacology in Yeast for Target Identification  | 455        |
| 16.5      | Identification of Protein Targets by Proteomic Analysis on 2D Gels   | 462        |
| 16.6      | Validation of Compound Targets by Biochemical Analysis   | 462        |
| 16.7      | Next Steps in Drug Development   | 464        |
| 16.8      | Concluding Remarks   | 466        |
|           | Acknowledgments  | 467        |
|           | Abbreviations  | 467        |
|           | References   | 467        |
| <b>17</b> | <b>Marine Natural Products: Biodiscovery, Biodiversity, and Bioproduction</b>  | <b>473</b> |
|           | <i>Miguel C. Leal and Ricardo Calado</i>   |            |
| 17.1      | Introduction   | 473        |
| 17.2      | Biodiscovery: What and Where?  | 474        |
| 17.2.1    | Taxonomic Trends   | 475        |
| 17.2.2    | Geographical Trends  | 478        |
| 17.3      | Biodiversity   | 481        |
| 17.3.1    | Exploring Marine Biodiversity  | 481        |
| 17.3.2    | Protecting Marine Biodiversity   | 483        |
| 17.4      | From Biodiscovery to Bioproduction   | 484        |
| 17.5      | Concluding Remarks   | 486        |
|           | References   | 487        |
|           | <b>Index</b>   | <b>491</b> |